Moreover, considering the suggestive observations reported in the present report, further investigation of the correlation between circulating CD26+ LSCs and the BCR::ABL1 transcript levels relating to the identification of new CML patient sub-settings is warranted. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.